Quest Diagnostics Inc (DGX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Quest Diagnostics Inc (DGX) stock forecast summary
Our AI ranks Quest Diagnostics Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Quest Diagnostics Inc is a large-cap company with a market capitalization of $25.94B. It ranks number 2 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast. Its Gross Margin of -70172.7% is the lowest of the 16 peers that report one.
For DGX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, DGX included.
Follow DGX freeDGX price chart and AI forecast
How DGX ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Quest Diagnostics Inc (DGX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | DGX | Rank |
|---|---|---|
| Market Cap | $25.94B | 2/29 |
| P/E Ratio | 24.95x | 5/6 |
| P/B Ratio | 3.45x | 9/22 |
| Dividend Yield | 1.40% | – |
| EPS | $9.42 | – |
| Book Value/Share | $68.10 | – |
| Revenue/Share | $0.10 | – |
| FCF/Share | $12.22 | – |
Profitability & Margins
| Metric | DGX | Rank |
|---|---|---|
| ROE | 14.1% | 2/14 |
| ROA | 6.3% | 3/20 |
| ROIC | 10.8% | 4/24 |
| Gross Margin | -70172.7% | 16/16 |
| Operating Margin | 14818.2% | 1/23 |
| Net Margin | 9654.5% | 2/17 |
| EBT Margin | 13027.3% | 1/23 |
| Tax Rate | 22.3% | – |
Financial Health
| Metric | DGX | Rank |
|---|---|---|
| Current Ratio | 1.59x | 19/26 |
| Quick Ratio | 1.46x | 10/11 |
| D/E Ratio | 1.21x | 6/22 |
| Financial Leverage | 2.25x | 7/22 |
| Working Capital | $1.06B | 3/26 |
Cash Flow
| Metric | DGX | Rank |
|---|---|---|
| Operating Cash Flow | $1.90B | 1/27 |
| Free Cash Flow | $1.35B | 1/17 |
| Capital Spending | -$554M | 17/17 |
| OCF Growth YoY | 13.4% | 5/7 |
| FCF Growth YoY | 10.2% | 2/5 |
| FCF/Sales | 12263.6% | 1/16 |
| CapEx/Sales | 5036.4% | 1/16 |
Operational Efficiency
| Metric | DGX | Rank |
|---|---|---|
| Asset Turnover | 0.00x | 17/18 |
| Receivables Turnover | 0.0x | 19/19 |
| Inventory Turnover | 33.2x | 2/7 |
| Fixed Assets Turnover | 0.0x | 17/17 |
| Days Sales Outstanding | 55281 days | 1/19 |
| Days Inventory | 11 days | 6/7 |
| Payables Period | 75 days | 6/14 |
| Cash Conversion Cycle | 55216 days | 1/6 |
Income Statement
| Metric | DGX | Rank |
|---|---|---|
| Total Revenue | $11M | 17/19 |
| Operating Income | $1.63B | 1/26 |
| Net Income | $1.06B | 1/20 |
| SG&A Expense | $2.04B | 2/20 |
| Cost of Goods Sold | $7.73B | 2/15 |
Dividend & Shareholder Information
| Metric | DGX | Rank |
|---|---|---|
| Dividends Per Share | $3.29 | – |
| Payout Ratio | 34.9% | – |
| Shares Outstanding | 110M | – |
| Net Income Growth | 11.8% | 4/5 |
| EPS Growth | 12.8% | 4/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $2.84B | 16.8% of assets |
| Cash & Short-term Investments | $626M | 3.7% of assets |
| Accounts Receivable | $1.67B | 9.8% of assets |
| Inventory | $233M | 1.4% of assets |
| Total Liabilities | $9.12B | 53.8% of assets |
| Short-term Debt | $190M | 1.1% of assets |
DGX quarterly financials and insider trading
Quest Diagnostics Inc (DGX) industry peers
Companies classified under the same SEC industry code as Quest Diagnostics Inc (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| NTRA Natera, Inc. | ▲ | $56.71B |
| LH Labcorp Holdings Inc. | ▶ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▶ | $2.14B |
| PSNL Personalis, Inc. | ▼ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $139M |
| SERA Sera Prognostics, Inc. | ▼ | $80M |
| CFOR Capforce Inc. | ▶ | $43M |
| MDXH Mdxhealth Sa | ▲ | $20M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▶ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▼ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▶ | $260K |
| RNLXY Renalytix Plc | ▲ | N/A |
Where DGX sits on the market map
Quest Diagnostics Inc (DGX) stock news
Loading...
Quest Diagnostics Inc (DGX) stock forecast FAQ
What is the Quest Diagnostics Inc (DGX) stock forecast?
Our AI ranks Quest Diagnostics Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Quest Diagnostics Inc stock predictions?
For DGX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Quest Diagnostics Inc forecasts updated?
Quest Diagnostics Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Quest Diagnostics Inc's industry peers?
30 issuers in our coverage, DGX included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT), Grail, Inc. (GRAL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.